60 Degrees Pharmaceuticals announced a private placement offering of 574,713 shares and warrants at $1.74 each, expected to raise about $1 million before fees. The offering includes series A and B warrants exercisable at $1.49 per share, with expiration terms of five years and two years respectively. Proceeds will support working capital and general corporate purposes. The company specializes in medicines for vector-borne diseases and has FDA-approved malaria prevention drug ARAKODA® available in the US and Australia.
iBUYPOWER, known for gaming PCs, has expanded into professional workstations with its new iBUYPOWER PRO line, targeting creative and technical professionals. These systems feature high-end Intel and AMD CPUs, NVIDIA and AMD GPUs, and come with a new ...
Glaukos reported a better-than-expected Q2 2026 with an adjusted loss of $0.14 per share, beating estimates, and revenues up 50% to $185.6 million, driven by strong sales of its iDose TR product. The company raised its 2026 sales guidance to $680-$70...
RBC Capital upgraded Glencore's price target to 610 GBp and maintained an "Outperform" rating, reflecting confidence in the company's growth. Glencore secured a key processing deal with HES International to supply Germany's Wilhelmshaven refinery, ex...
Bloom Energy reported a record revenue of $1.07 billion in Q2 2026, significantly surpassing estimates of $826.13 million. The company also doubled earnings per share expectations with an EPS of $0.78, signaling strong profitability. Following these ...
Bombardier reported strong Q2 2026 results with adjusted EPS of $2.50, beating estimates of $1.32, and revenue of $2.15 billion, surpassing expectations. The growth was mainly fueled by a record $674 million from its Services division, which grew 14%...
